Subscribe
Webinars
White Papers
Buyer's Guide
PhotonicsNXT
Get Published!
Lasers/Sources
Detectors/Imaging
Optics
Bio & Life Sciences
Laser Processing
Test/Measurement
Science & Research
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
BioOptics Stock Watch
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
ImmunityBio, Inc. - Common Stock
(NQ:
IBRX
)
6.450
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 23, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about ImmunityBio, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
IBRX Stock Gains Pre-Market After A Volatile Trading Session Following Phase 2 Glioblastoma Trial Update: Retail Backs ImmunityBio’s Cancer Research
↗
Today 7:06 EST
Patrick Soon Shiong, ImmunityBio’s founder, took to X on Saturday to clarify what the update signified.
Via
Stocktwits
Topics
Death
ETFs
Nasdaq, S&P 500 Futures Open The Week On Edge As Earnings, Tariffs, Fed Decision Loom: Why META, NVDA, RVMD, USAR Are On Traders' Radar Today
↗
Today 3:22 EST
Via
Stocktwits
Topics
Economy
Stocks
$5 Stocks: NDRA, IBRX, MOVE, RVLY Drawing Attention Watch Now!
January 25, 2026
Via
AB Newswire
Stock Market Today, Jan. 23: ImmunityBio Falls After Gaining Over 200% in a Month
↗
January 23, 2026
Today, Jan. 23, 2026, profit taking and fresh glioblastoma survival data weighed on a soaring biotech stock.
Via
The Motley Fool
Topics
Stocks
IBRX Stock Extends Rally On FDA Feedback For ANKTIVA Bladder Cancer Filing
↗
January 20, 2026
Via
Stocktwits
Why IBRX Stock Is One Of The Biggest Pre-Market Movers Today
↗
January 16, 2026
Via
Stocktwits
IBRX Stock Continues Rally — What’s Driving The Optimism Today?
↗
January 15, 2026
Via
Stocktwits
IBRX Stock Sees Volatile Session – ImmunityBio’s Update In Phase 2 Glioblastoma Trial Sparks Buzz
↗
January 23, 2026
ImmunityBio stated that it has not yet achieved median survival in patients receiving Anktiva + CAR-NK treatment in the trial.
Via
Stocktwits
Topics
Death
ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy
January 23, 2026
From
ImmunityBio, Inc.
Via
Business Wire
Stock Market Today, Jan. 21: ImmunityBio Rises Again As Short-Sellers Face Losses
↗
January 21, 2026
On Jan. 21, 2026, the market weighed ImmunityBio’s skyrocketing share price, surging volume, and the company's heavily-shorted stock.
Via
The Motley Fool
Topics
Stocks
IBRX Stock Finds Retail Cheer After Company’s Immunotherapy For Bladder Cancer Gets Saudi FDA Approval
↗
January 14, 2026
Via
Stocktwits
Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer
↗
January 20, 2026
On Jan. 20, 2026, investors weigh ImmunityBio’s sharp rally on new FDA feedback around its bladder cancer plans.
Via
The Motley Fool
Topics
Stocks
Which stocks are most active on Tuesday?
↗
January 20, 2026
Via
Chartmill
ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer
January 20, 2026
From
ImmunityBio, Inc.
Via
Business Wire
Nasdaq, S&P 500 Futures Slide As Trump Ramps Up Greenland Threats: Why NFLX, CRML, TSLA, VERO, SRXH Are On Traders' Radar Today
↗
January 20, 2026
Retail sentiment on Stocktwits has flipped bearish on SPY and QQQ amid elevated message volumes and rising volatility.
Via
Stocktwits
Topics
Artificial Intelligence
ETFs
Economy
Why Is ImmunityBio Stock Back In Retail Spotlight Today?
↗
January 19, 2026
The company outlined progress across multiple cancer programs following last week's series of clinical and regulatory updates.
Via
Stocktwits
Nasdaq, S&P 500 Futures Slide On Greenland Tensions: Why NVDA, MU, IBRX, CRML And VERO Are On Traders’ Radar Today
↗
January 19, 2026
Via
Stocktwits
Topics
Stocks
Stock Market Today, Jan. 16: ImmunityBio Soars After Anktiva Revenue Jumps 700 Percent Year Over Year
↗
January 16, 2026
Explosive Anktiva sales, new cancer data, and fresh approvals are rapidly redefining this immunotherapy story, today, Jan. 16, 2026.
Via
The Motley Fool
Topics
Stocks
Which stocks are experiencing notable movement on Friday?
↗
January 16, 2026
Via
Chartmill
Why ImmunityBio Stock Is Skyrocketing Again Today
↗
January 16, 2026
It has been an incredible week of positive news for ImmunityBio.
Via
The Motley Fool
Curious about the most active stocks on Friday?
↗
January 16, 2026
Via
Chartmill
Keep an eye on the top gainers and losers in Friday's session.
↗
January 16, 2026
Via
Chartmill
Friday's session: gap up and gap down stocks
↗
January 16, 2026
Via
Chartmill
ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma
January 16, 2026
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG
January 16, 2026
From
ImmunityBio, Inc.
Via
Business Wire
Stock Market Today, Jan. 15: ImmunityBio Surges After Anktiva Revenue Jumps 700%
↗
January 15, 2026
On Jan. 15, 2026, investors took note of Anktiva's explosive sales ramp, its geographic expansion potential, and a possible new indication.
Via
The Motley Fool
Topics
Earnings
Stocks
Thursday's session: top gainers and losers
↗
January 15, 2026
Via
Chartmill
Which stocks are moving on Thursday?
↗
January 15, 2026
Via
Chartmill
ImmunityBio Reports Continued Execution and Sales Momentum With $113 Million of Preliminary Net Product Revenue—a 700% increase year-over-year
January 15, 2026
From
ImmunityBio, Inc.
Via
Business Wire
MAGA SmallCaps Watchlist: ROLR, SURG, IBRX, BNAI, NDRA – January 2026 Focus
January 14, 2026
Via
AB Newswire
Topics
Derivatives
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
